Skip to main content
padlock icon - secure page this page is secure

1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome

Buy Article:

$47.00 + tax (Refund Policy)

Nückel H, Frey UH, Dürig J, Dührsen U, Siffert W. 1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome.

Eur J Haematol 2004: 72: 259–263. © Blackwell Munksgaard 2004 Abstract:

Purinergic P2X7 receptors are ligand-gated cation channels expressed on the cells of the immune and hemopoietic system which have been shown to mediate the ATP-induced apoptotic death of monocytes, macrophages and lymphocytes. A common single nucleotide polymorphism within the P2X7 gene has been described in exon 13 (1513A/C), the gene products encoding fully active and non-functional proteins. We genotyped the P2X7 1513A/C polymorphism using DNA from 111 patients with chronic lymphocytic leukemia (CLL) and 97 healthy controls using polymerase chain reaction (PCR) amplification followed by Hha1 restriction analysis. We found no significant difference in allele frequency between CLL patients and controls. Time periods from diagnosis to initiation of chemotherapy, a surrogate marker for disease progression, were not different in patients displaying the combined 1513A/C and C/C or the 1513A/A genotype (P = 0.97). Similar results were observed in a subgroup analysis of prognostically more favorable CD38-negative and ZAP-70-negative CLL patients. In conclusion, our data do not support a role of the P2X7 genotype as a prognostic marker in B-cell CLL.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: P2X7 receptor; chronic lymphocytic leukemia

Document Type: Research Article

Affiliations: 1: Institute of Pharmacology, Medical Faculty, University of Essen, Essen, Germany 2: Department of Hematology

Publication date: 01 April 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more